Maxim Soloviev Selected Research

Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)

1/2020

Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maxim Soloviev Research Topics

Disease

4	Neoplasms (Cancer) 01/2022 - 01/2018
1	Lymphoma (Lymphomas) 01/2020
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Pain (Aches) 01/2012

Drug/Important Bio-Agent (IBA)

1	AntibodiesIBA 01/2022
1	LigandsIBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	pemigatinibIBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	parsaclisibIBA 01/2020
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2018
1	Bendamustine Hydrochloride FDA Link 01/2018
1	CarrageenanIBA 01/2012
1	1- (7- (2- amino- 6- (4- methylpiperazin- 1- yl)pyrimidin- 4- yl)- 3,4- dihydroisoquinolin- 2(1H)- yl)- 2- cyclopentylethanoneIBA 01/2012
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2012
1	Formaldehyde (Formol)FDA Link 01/2012

Therapy/Procedure

2	Therapeutics 01/2020 - 01/2018
1	Drug Tapering 01/2020